From the Research
Allegra (fexofenadine) is not recommended for infants under 2 years of age, and there is no established dose for a 9-month-old baby. The most recent and highest quality study, 1, published in 2021, highlights the need for more data on the efficacy and safety of fexofenadine in children under 6 years, emphasizing the importance of caution when considering its use in young children.
Key Considerations
- The FDA has not approved Allegra for infants under 2 years, and pediatricians generally advise against its use in this age group due to the lack of studies on safety and efficacy 1.
- The metabolic systems of infants are still developing, making dosing complex and potentially risky 2.
- Alternative approaches, such as avoiding allergens, using saline nasal sprays, or prescribing age-appropriate medications, may be recommended by pediatricians for infants with allergy symptoms 1.
Recommendations
- For infants with allergy symptoms, it's best to consult with a pediatrician for proper evaluation and treatment recommendations tailored to the child's specific needs 1.
- Given the potential risks and lack of established safety and efficacy data, it is not advisable to administer Allegra to a 9-month-old baby without consulting a pediatrician 3.
Safety and Efficacy
- Studies have shown that fexofenadine has a favorable safety profile compared to first-generation antihistamines, with less sedation and cognitive impairment 4, 3.
- However, the safety and efficacy of fexofenadine in infants under 2 years have not been adequately studied, making it essential to prioritize caution and consult with a pediatrician before use 1.